On the integration of early health technology assessment in the innovation process: reflections from five stakeholders
| Autor: | Markus Siebert, Janneke P.C. Grutters, Kari J. Kværner, Øyvind Melien, Marcia Tummers, Laura Sampietro-Colom, Murray Krahn, Payam Abrishami, Dominique Hamerlijnck |
|---|---|
| Přispěvatelé: | Erasmus School of Health Policy & Management |
| Rok vydání: | 2020 |
| Předmět: |
Value (ethics)
Process management Technology Assessment Biomedical Process (engineering) 030503 health policy & services Health Policy Best practice Policy maker Innovation process Health technology Variety (cybernetics) Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] 03 medical and health sciences 0302 clinical medicine Stakeholder Participation Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] Assessment methods 030212 general & internal medicine Business Diffusion of Innovation 0305 other medical science Policy Making |
| Zdroj: | International Journal of Technology Assessment in Health Care. Cambridge University Press International Journal of Technology Assessment in Health Care, 36, 5, pp. 481-485 International Journal of Technology Assessment in Health Care, 36, 481-485 International Journal of Technology Assessment in Health Care |
| ISSN: | 0266-4623 |
| Popis: | Contains fulltext : 229282.pdf (Publisher’s version ) (Open Access) Early health technology assessment (HTA), which includes all methods used to inform industry and other stakeholders about the potential value of new medical products in development, including methods to quantify and manage uncertainty, has seen many applications in recent years. However, it is still unclear how such early value assessments can be integrated into the technology innovation process. This commentary contributes to the discussion on the purposes early HTA can serve. Similarities and differences in the perspectives of five stakeholders (i.e., the hospital, the patient, the assessor, the medical device industry, and the policy maker) on the purpose, value, and potential challenges of early HTA are described. All five stakeholders agreed that integrating early HTA in the innovation process has the possibility to shape and refine an innovation, and inform research and development decisions. The early assessment, using a variety of methodologies, can provide insights that are relevant for all stakeholders but several challenges, for example, feasibility and responsibility, need to be addressed before early HTA can become standard practice. For early evaluations to be successful, all relevant stakeholders including patients need to be involved. Also, nimble, flexible assessment methods are needed that fit the dynamics of medical technology. Best practices should be shared to optimize both the innovation process and the methods to perform an early value assessment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|